Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system

다국어 초록 (Multilingual Abstract)

Objective: To determine whether less invasive endometrial (EM) aspiration biopsy is adequately accurate for evaluating treatment outcomes compared to the dilatation and curettage (D&C) biopsy in early-stage endometrial cancer (EC) patients treated with high dose oral progestin and levonorgestrel intrauterine system (LNG-IUS).
Methods: We conducted a prospective observational study with patients younger than 40 years who were diagnosed with clinical stage IA, The International Federation of Gynecology and Obstetrics grade 1 or 2 endometrioid adenocarcinoma and sought to maintain their fertility. The patients were treated with medroxyprogesterone acetate 500 mg/day and LNG-IUS. Treatment responses were evaluated every 3 months. EM aspiration biopsy was conducted after LNG-IUS removal followed D&C. The tissue samples were histologically compared. The diagnostic concordance rate of the two tests was examined with κ statistics.
Results: Twenty-eight pairs of EM samples were obtained from five patients. The diagnostic concordance rate of D&C and EM aspiration biopsy was 39.3% (κ value=0.26). Of the seven samples diagnosed as normal with D&C, three (42.8%) were diagnosed as normal by using EM aspiration biopsy. Of the eight samples diagnosed with endometrioid adenocarcinoma by using D&C, three (37.5%) were diagnosed with endometrioid adenocarcinoma by using EM aspiration biopsy. Of the 13 complex EM hyperplasia samples diagnosed with the D&C, five (38.5%) were diagnosed with EM hyperplasia by using EM aspiration biopsy. Of the samples obtained through EM aspiration, 46.4% were insufficient for histological evaluation.
Conclusion: To evaluate the treatment responses of patients with early-stage EC treated with high dose oral progestin and LNG-IUS, D&C should be conducted after LNG-IUS removal.

참고문헌 (Reference)

1 Elsandabesee D, "The performance of Pipelle endometrial sampling in a dedicated postmenopausal bleeding clinic" 25 : 32-34, 2005

2 Pashov AI, "The combined GnRH-agonist and intrauterine levonorgestrelreleasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study" 28 : 559-561, 2012

3 Dijkhuizen FP, "The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis" 89 : 1765-1772, 2000

4 Sonoda Y, "Surgical treatment for apparent early stage endometrial cancer" 57 : 1-10, 2014

5 Soliman PT, "Risk factors for young premenopausal women with endometrial cancer" 105 : 575-580, 2005

6 Lee NK, "Prognostic factors for uterine cancer in reproductive-aged women" 109 : 655-662, 2007

7 Cade TJ, "Progestogen treatment options for early endometrial cancer" 117 : 879-884, 2010

8 Park JY, "Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer" 20 : 270-278, 2015

9 Brown AJ, "Progestin intrauterine device in an adolescent with grade 2 endometrial cancer" 119 (119): 423-426, 2012

10 Minig L, "Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women" 22 : 643-649, 2011

11 Kim YB, "Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature" 79 : 320-327, 1997

12 Trimble EL, "Pre-operative imaging, surgery and adjuvant therapy for women diagnosed with cancer of the corpus uteri in community practice in the United States" 96 : 741-748, 2005

13 Stovall TG, "Pipelle endometrial sampling in patients with known endometrial carcinoma" 77 : 954-956, 1991

14 Gotlieb WH, "Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer" 102 : 718-725, 2003

15 Ushijima K, "Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women" 25 : 2798-2803, 2007

16 Mahdi H, "Lymph node metastasis and pattern of recurrence in clinically early stage endometrial cancer with positive lymphovascular space invasion" 26 : 208-213, 2015

17 Fambrini M, "Levonorgestrelreleasing intrauterine system alone as primary treatment in young women with early endometrial cancer: case report" 16 : 630-633, 2009

18 Giannopoulos T, "Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma" 95 : 762-764, 2004

19 Dhar KK, "Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature" 97 : 924-927, 2005

20 Montz FJ, "Intrauterine progesterone treatment of early endometrial cancer" 186 : 651-657, 2002

21 van Doorn HC, "Inadequate office endometrial sample requires further evaluation in women with postmenopausal bleeding and abnormal ultrasound results" 99 : 100-104, 2007

22 Kesterson JP, "Fertility-sparing treatment of endometrial cancer: options, outcomes and pitfalls" 23 : 120-124, 2012

23 Crissman JD, "Endometrial carcinoma in women 40 years of age or younger" 57 : 699-704, 1981

24 Duska LR, "Endometrial cancer in women 40 years old or younger" 83 : 388-393, 2001

25 Goldstein SR, "Endometrial assessment by vaginal ultrasonography before endometrial sampling in patients with postmenopausal bleeding" 163 (163): 119-123, 1990

26 이정윤, "Controversies in the management of endometrial cancer: a survey of the Korean Gynecologic Oncology Group" 대한부인종양학회 26 (26): 277-283, 2015

27 Kaku T, "Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome" 167 : 39-48, 2001

28 Kim MK, "Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer" 130 : 470-473, 2013

29 Kim MK, "Combined medroxyprogesterone acetate/ levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer" 209 : 358-, 2013

30 김미라, "Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases" 대한산부인과학회 56 (56): 67-75, 2013

31 Creasman WT, "Carcinoma of the corpus uteri" 6 : 47-86, 2001

32 Siegel R, "Cancer statistics, 2014" 64 : 9-29, 2014

33 Clark TJ, "Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic quantitative review" 109 : 313-321, 2002